Molecular characterization of #kidneycancer allows for prediction of risk of recurrence. MERTK and TDO2 should be investigated in future trials. Amazing data from Robert Motzer MD Dan George Alain Ravaud and others. rdcu.be/cXe1y

Michael Staehler Dan George Alain Ravaud Kudos to Jean-Francois Martini and Keith Ching from Pfizer for providing the SCIENCE and their effort in getting this published. I hope it serves as a model for study of the IO adjuvant phase 3 trials in RCC.